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Gene targeting in mice was used to investigate the unknown function of Scp2, encoding sterol carrier
protein-2 (SCP2; a peroxisomal lipid carrier) and sterol carrier protein-x (SCPx; a fusion protein between SCP2
and a peroxisomal thiolase). Complete deficiency of SCP2 and SCPx was associated with marked alterations in
gene expression, peroxisome proliferation, hypolipidemia, impaired body weight control, and neuropathy.
Along with these abnormalities, catabolism of methyl-branched fatty acyl CoAs was impaired. The defect
became evident from up to 10-fold accumulation of the tetramethyl-branched fatty acid phytanic acid in
Scp2(−/−) mice. Further characterization supported that the gene disruption led to inefficient import of
phytanoyl-CoA into peroxisomes and to defective thiolytic cleavage of 3-ketopristanoyl-CoA. These results
corresponded to high-affinity binding of phytanoyl-CoA to the recombinant rat SCP2 protein, as well as high
3-ketopristanoyl-CoA thiolase activity of the recombinant rat SCPx protein.
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Sterol carrier protein-2 (SCP2) was isolated originally as
a ‘‘cytosolic’’ factor required for efficient in vitro conver-
sion of 7-dehydrocholesterol to cholesterol, catalyzed by
microsomal sterol-D7-reductase (Noland et al. 1980).
Subsequently, it was shown that the protein was identi-
cal to the nonspecific lipid transfer protein (ns-LTP),
which had been purified based on its ability to catalyze
the exchange of a variety of phospholipids between
membranes in vitro (Bloj and Zilversmit 1977). More re-
cently, it could be demonstrated that purified SCP2
binds fatty acids and fatty acyl Coenzyme A (CoA) with
similar or even higher affinity than sterols (Stolowich et
al. 1997). Cloning and sequencing of SCP2 cDNAs
showed that the protein comprises a carboxy-terminal
SKL peroxisomal targeting signal (Seedorf and Assmann
1991), and immunocytochemical studies confirmed the
predominant localization of SCP2 within peroxisomes
(Keller et al. 1989; Ossendorp and Wirtz 1993). Several
lines of indirect evidence exist that appear to support a
role of SCP2 in adrenal and ovarian steroidogenesis (for
review, see Pfeifer et al. 1993a). In addition, cell culture
studies suggested a potential participation of SCP2 in
cytosolic sterol transport to the plasma membrane
(Puglielli et al. 1995; Baum et al. 1997). However, the
localization of SCP2 in peroxisomes makes it difficult to
understand how the protein might carry out these func-
tions in the intact cell. Thus, the biological function of
SCP2 is not clear.
The SCP2-encoding gene (Scp2) comprises 16 exons,
spanning ∼100 kb on human chromosome 1p32. Tran-
scription initiation is controlled by two distant promot-
ers that were mapped immediately upstream of the first
exon (P1) and exon 12 (P2) (Ohba et al. 1994, 1995). P2 is
used to generate SCP2-encoding transcripts, which com-
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bine the coding information provided by exons 12–16. In
addition, alternate transcription initiation at P1 leads to
production of a second transcript that includes the cod-
ing information provided by exons 1–16. The respective
gene product consists of 547 amino acids and was named
sterol carrier protein-x (SCPx) (Seedorf and Assmann
1991). SCPx represents a fusion protein between a thio-
lase domain, extending from amino acids 1–404, and
SCP2, which is located at the carboxyl terminus (Ossen-
dorp et al. 1991). It is known from previous in vitro stud-
ies that SCPx has similar lipid transfer activity as SCP2
and that the substrate specificity of the SCPx thiolase
shows a preference for straight medium chain acyl-CoA
substrates and tetramethyl-branched 3-ketopristanoyl-
CoA (Seedorf et al. 1994a; Wanders et al. 1997). Thus, the
SCPx-associated thiolase differs from the initially iden-
tified peroxisomal thiolase that is assumed traditionally
to play a major role in peroxisomal b-oxidation of most
naturally occurring substrates, including bile acids and
very long chain fatty-acids (VLCFA) (Hijikata et al. 1987;
Schram et al. 1987).
In the present study, we investigated the biological
function of Scp2 by using gene targeting in mice. The
phenotypic abnormalities of the Scp2(−/−) knockout
(KO) mice revealed a profound impact of the gene dis-
ruption on the in vivo degradation of branched-chain
fatty acyl-CoAs coming from the metabolism of tetra-
methyl-branched fatty acid phytanic acid. On the other
hand, the serum concentrations of cholesterol, steroids,
VLCFA, and long-chain fatty acids were not affected in
Scp2(−/−) mice. This leads to our conclusion that one
principal function of Scp2 resides in the major peroxi-
somal pathway, which mediates the degradation of
methyl-branched fatty acyl-CoA substrates in mice.
Results
To produce SCP2 and SCPx deficiency, we introduced a
gene disruption at the exon 14 region of the gene (Fig.
1A). Transfection of the targeting vector into mouse E14
ES cells and subsequent positive–negative selection pro-
vided 182 clones. Southern blot analysis led to the iden-
tification of two correctly targeted clones (cl20, cl110)
with only a single neo gene copy in the targeted locus
(Fig. 1B). Injection of recombinant cl110 embryonic stem
cells in blastocysts obtained from C57BL/6 donors, fol-
lowed by embryo transfer into CD1 foster mothers gen-
erated five chimeras. Among these, we identified three
transmitters that were crossed further with C57BL/6
mice.
Complete elimination of the Scp2 gene function was
confirmed by Northern blot experiments, showing a low-
intensity signal derived from a truncated Scp2 transcript
in (−/−) mice that was ∼150 nucleotides smaller than the
corresponding transcript in normal C57BL/6 mice (Fig.
1C). When primers, flanking the region of the Scp2
cDNA encoded by exon 14, were used for PCR amplifi-
cation with reverse transcribed poly(A) RNA, isolated
from (−/−) mice, a DNA fragment was obtained that
again was ∼150 bp smaller than normal. DNA sequenc-
ing of this DNA fragment revealed that the Scp2 targeted
allele led to abnormal splicing resulting in exon 14 skip-
ping (Fig. 1D). The cDNA sequence predicted protein
sequences of SCP2 and SCPx that were normal until po-
sition 22 and 427, respectively. Thereafter, the direct
junction to the coding information of exon 15 resulted in
a frame-shift, thereby creating a premature stop 18
codons downstream. Results from earlier site-directed
mutagenesis studies lead to the conclusion that the pre-
dicted SCP2 variant should clearly lack any residual lipid
transfer activity (Seedorf et al. 1994b). In contrast, the
thiolase-like domain (residues 1–404) was preserved in
the predicted SCPx variant, which may suggest the pos-
sibility of residual thiolase activity. However, because
the carboxy-terminal peroxisomal targeting signal is ab-
sent, the variant should no longer be imported into per-
oxisomes and therefore, should be at least functionally
inactive. Moreover, as shown in Figure 1E, liver extracts
subjected to Western blot analyses developed with anti-
SCP2 or anti-SCPx antibodies revealed complete absence
of the two proteins in (−/−) mice. Homozygous trans-
genes also lacked the previously identified peroxisomal
44-kD thiolase-like peptide that was considered to result
from proteolytic processing of SCPx (Seedorf et al.
1994a).
Genotyping showed that heterozygous (+/−) and ho-
mozygous (−/−) transgenes were viable. When kept under
standard laboratory conditions, (−/−) mice developed
normally and had no developmental abnormalities. We
did not observe differences in the incidence of (+/+),
(+/−), and (−/−) mice from the Mendelian distribution
[27% (+/+), 52% (+/−), 21% (−/−), n = 141] indicating that
the (−/−) allele did not affect the viability at 3–4 weeks of
age. In addition, (−/−) males and females reached fertility
at the normal age of ∼6 weeks. Interbreeding between
(−/−) males and (−/−) females gave rise to viable progeny.
The litters were of comparable sizes as that found in
(+/+) or (+/−) interbreeding. In 6- to 8-week-old males,
testosterone and glucocorticoid concentrations were
within the normal range. No differences between the
two strains were also found for progesterone in nonpreg-
nant females under baseline conditions. Whereas plasma
insulin and cholesterol concentrations were normal, tri-
glycerides were slightly higher and free fatty acid and
glucose concentrations were moderately lower in (−/−)
mice (Table 1).
All major tissues of the Scp2(−/−) mice were examined
by light microscopy at various times after birth and com-
pared with those of heterozygous and wild-type mice.
Although the organ systems appeared morphologically
normal, we observed more intense diaminobenzidine
staining (DAB, stains specifically peroxisomes) in frozen
liver sections from Scp2(−/−) mice than from controls
(Fig. 2A). Enzyme activity levels of the peroxisomal
marker catalase were 1.8-fold elevated in Scp2(−/−) liver.
Likewise, peroxisomal palmitoyl-CoA oxidase (ACO),
mitochondrial butyryl-CoA dehydrogenase, and total
3-ketooctanoyl-CoA thiolase activities were all two- to
threefold higher in Scp2(−/−) mice than in controls (Fig.
2B). Whereas the hepatic levels of phospholipids were
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normal, cholesterol ester and triglyceride storage pools
were markedly depleted in livers from Scp2(−/−) mice
(Table 1). Intestinal lipid absorption was normal, as
judged by monitoring intestinal uptake of radiolabeled
cholesterol or palmitic acid. We also did not detect ab-
normal liver function, as indicated by normal GOT,
GPT, gGT, and bilirubin serum levels (data not shown).
Age- and sex-matched Scp2(−/−) and C57BL/6 mice had
similar body weights, whereas food intake was signifi-
cantly higher in Scp2(−/−) mice (256 ± 12.9 mg/
day × grams of body weight) compared with controls
(196 ± 10.7 mg/day × grams of body weight).
In addition to these biochemical abnormalities, the
Scp2 gene disruption had marked effects on hepatic gene
expression. As shown in Figure 3, Scp2(−/−) mice showed
increased expression of liver fatty acid-binding protein
(L-FABP, fourfold), peroxisomal 3-ketoacyl-CoA thiolase
(pTHIOL, three- to fourfold), mitochondrial 3-ketoacyl-
CoA thiolase (mTHIOL, two- to threefold), ACO (two-
fold), and cholesterol-7a-hydroxylase (CYP7a, fourfold).
Figure 1. Targeted disruption of the murine Scp2 gene by homologous recombination. (A) Structures of the Scp2 gene (top), the exon
14 region of the locus, the Scp2 targeting vector, and the targeted Scp2 locus after homologous recombination (bottom). Only relevant
restriction sites are shown: (H3) HindIII; (R1) EcoRI; (R5) EcoRV; (S) SpeI. The SalI site (S1), shown in exon 14, was not present in the
originally isolated genomic clone, but was introduced by site-directed mutagenesis to enable introduction of the neo gene cassette (see
Materials and Methods for details). The neo gene and HSV-tk gene cassettes are indicated by boxes. The location of the vector pPNT
is shown schematically by bend lines. The scale is indicated by the bars above the gene structure and the exon 14 region. The positions
of the relevant probes are marked by open boxes. (B) Southern blot analysis with digested ES cell genomic DNA of a correctly targeted
ES cell line (left, clone 110) and the parental cell line E14 (control), right. The sizes (in kb) of DNA fragments obtained after
hybridization with probe I for the correctly targeted and the original allele are shown on either side. (C) Northern blot analysis of
mouse liver RNA. Total RNA (20 µg) from wild-type (+/+) and Scp2(−/−) mice was used and hybridized to a labeled Scp2 cDNA probe.
The four normal Scp2 transcripts of 2700 nucleotides (scpx), the major 1500-nucleotide SCP2 transcript (scp2), and two minor
alternatively polyadenylated transcripts (scp2*, 900 nucleotides; scpx*, 2200 nucleotides) are indicated. The sample from the homo-
zygous Scp2(−/−) mouse provided a low-intensity signal of a transcript of ∼2550 nucleotides (scpxko). As a control for identical sample
loading the same Northern blot analysis was reprobed with a rat GADPH cDNA probe (bottom). (D) Direct DNA sequencing of the
Scp2 transcript from liver of (−/−) mice. The sequence is shown along with the translated amino acid sequence. The normal protein
sequence is in boldface type. The shift of the normal reading frame that is caused by the direct junction of exons 13–15 is indicated
by an arrow. The codon numbers (left) refer to the normal mouse SCP2 and SCPx cDNAs. (***) The location of the premature stop
codon. (E) Western blot analysis of mouse liver proteins. The blots were developed with either polyclonal antibodies raised against
recombinant rat SCP2, anti-SCP2, or antibodies raised against a recombinant 383-amino-acid amino-terminal peptide of SCPx (anti-
SCPx). Arrows indicate bands corresponding to SCP2 (13.5 kD), SCPx (60 kD), and the 44-kD thiolase-like peptide (44-kD peptide). No
specific reactivity was obtained with samples from (−/−) mice.
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In contrast, no effect was observed on the level of
GAPDH, b-actin, and sterol-27-hydroxylase (CYP27) ex-
pression, whereas phosphoenolpyruvate carboxykinase
(PEPCK) expression was down-regulated in the Scp2(−/−)
group, which corresponded to mild hypoglycemia in that
group (Fig. 3, Table 1).
Whereas we did not detect significant differences re-
garding the relative levels of the straight long chain satu-
rated, monounsaturated, polyunsaturated, or VLCFAs
(data not shown), phytanic acid was close to 10-fold el-
evated in (−/−) mice compared with controls (Table 2).
Phytanic acid is a tetramethyl-branched fatty acid that is
produced in heterotrophic organisms from plant-derived
phytol (an isoprenoic alcohol esterified to ring IV of chlo-
rophyll). Because neither phytanic acid nor phytol are
synthesized de novo in mammals, phytanic acid serum
concentrations depend on dietary intake of preformed
phytanic acid or its precursor phytol, storage of phytanic
acid in cellular neutral lipids, and the catabolic rate of
phytanic acid (Steinberg 1995). Because only low
amounts of free phytol (75 µg/gram) and phytanic acid
(200 µg/gram) were present in the normal laboratory
diet, we performed feeding experiments with semisyn-
thetic diets supplemented with phytol. When Scp2(−/−)
mice were exposed to a diet containing 5 mg/g of phytol
for 7 days, the levels in serum of phytanic acid increased
from 16 to 1163 µmoles/liter, whereas in Scp2(+/+) mice,
it increased from 1.4 to 129 µmoles/liter (Table 2). Like-
wise, when we used a more natural high-fat diet (con-
taining 15% coconut butter, which is a rich natural
source of phytanic acid and phytol), phytanic acid
plasma levels were more than tenfold higher in Scp2(−/−)
mice compared with controls. In addition, elevated phy-
tanic acid concentrations were also detected in sera from
heterozygotes (Table 2).
We then exposed male mice of the two strains to phy-
tol-enriched diets for 4 days, followed by a period of 10
days in which they were fed the standard low-phytol
diet. In (+/+) mice, dietary intake of the phytol-enriched
food induced an increase in serum phytanic acid concen-
trations up to 69 µmoles/liter (Fig. 4). After the diet
change, the concentrations declined to 1.5 µmoles/liter
within 2 days. In (−/−) mice phytanic acid reached a
maximum of 354 µmoles/liter and declined to 36
µmoles/liter at day 10. Thereafter, phytanic acid contin-
ued to decline slowly, reaching 18 µmoles/liter at the
end of the experiment. In contrast to (+/+) mice, who
revealed a close to twofold transient increase with re-
spect to liver catalase activities, the values remained
close to twofold above normal in (−/−) mice throughout
the experiment (Fig. 4).
Catabolism of phytanic acid proceeds by way of a-oxi-
dation, yielding the (n − 1) lower homolog pristanic acid
(C19:0), which is further catabolized by way of b-oxida-
tion in peroxisomes (Singh et al. 1994; Singh and Poulos
1995; Steinberg 1995). To discriminate between defec-
tive phytanoyl-CoA a-oxidation and pristanoyl-CoA
b-oxidation, we then quantified pristanic acid. How-
ever, pristanic acid could not be detected in sera from
Scp2(+/+), Scp2(+/−), or Scp2(−/−) mice under normal
conditions. Only after phytol enrichment of the diet,
pristanic acid concentrations were two- to threefold
higher in Scp2(−/−) mice than in the two other strains
(Table 2). To investigate the block in phytol catabolism
more specifically, we continued to analyze phytol me-
tabolites in saponified liver lipid extracts by time-of-
flight secondary-ion-mass-spectrometry (TOF-SIMS)
(Fig. 5A). This method enabled us to detect a wider range
of metabolites than could be identified by gas chroma-
tography. Evaluation of the signal intensities of the rel-
evant ions indicated accumulation of phytanic acid (six-
to eightfold), D2,3-pristenic acid (four- to fivefold), 3-OH-
pristanic acid (three- to fourfold), and pristanic acid (two-
fold) in (−/−) liver (Fig. 5C). Because model analyses with
3-ketoacyl acids indicated that they were not stable dur-
ing the analysis (data not shown), 3-ketopristanic acid
could not be measured directly. However, we looked for
the product of the thiolytic cleavage of 3-ketopristanoyl-
CoA, detected at 255.3 mu (corresponding to the [M-H+]−
ion of 4,8,12-trimethyltridecanoic acid; TMTDA). As ex-
pected for deficient thiolytic cleavage of 3-ketopris-
tanoyl-CoA, the respective signal was found 70% re-
Table 1. Laboratory values in Scp2 (−/−), Scp 2 (+/−) mice, and controls
Unit Scp2 (+/+) Scp2 (+/−) Scp2 (−/−)
Testosterone (serum) nmoles/liter 3.0 ± 1.8 4.9 ± 2.2 2.0 ± 0.9
Progesterone (serum, /) nmoles/liter 11.2 ± 6.9 12.5 ± 8.6 10.4 ± 3.0
Corticosteroids (serum) ng/dl 188 ± 32 210 ± 44 204 ± 35
Insulin (serum) ng/dl 161 ± 34 187 ± 40 207 ± 34
Cholesterol (serum) mg/dl 71 ± 11 104 ± 20 66 ± 17
Triglycerides (serum) mg/dl 89 ± 3 89 ± 16 105 ± 4*
Free fatty acids (serum) mM 1.12 ± 0.09 1.08 ± 0.10 0.72 ± 0.04*
Glucose (serum) mg/dl 116 ± 13 108 ± 7 81 ± 3
Phospholipids (liver) mg/gram 20.5 ± 1.2 19.7 ± 2.4 19.3 ± 2.6
Cholesterol (liver) mg/gram 3.2 ± 0.3 2.9 ± 0.4 2.9 ± 0.4
Cholesterol ester (liver) mg/gram 0.50 ± 0.12 0.47 ± 0.09 0.25 ± 0.06*
Triglycerides (liver) mg/gram 66.2 ± 8.5 41.7 ± 9.5* 32.8 ± 6.9*
Values represent means ±S.E.M.; (*) P ø 0.05 (comparison to controls with the paired t-test; (n ù 5). Progesterone was measured in
nonpregnant 8- to 12-week-old females. All other values are from 8- to 12-week-old males.
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pressed in Scp2(−/−) mice (Fig. 5B,C). Likewise, the sig-
nal of the next predicted downstream metabolite, 4,8,12-
trimethyl-D2,3-tridecenoic acid (D2,3-TMTDA), was also
close to threefold higher in controls than in the trans-
genic strain (Fig. 5B,C). In contrast, signals expected for
phytol (detected as a negative ion at 293.5 mu) were
barely detectable in all samples, suggesting that conver-
sion of phytol to phytanic acid occurred with high effi-
ciency in both strains of mice.
These data support the concept that phytol degrada-
tion is inhibited at a step downstream of phytanoyl-CoA
a-oxidation. They are also in line with recent findings by
Wanders et al. (1997) that purified recombinant rat SCPx
protein exhibits high 3-keto-pristanoyl-CoA thiolase ac-
tivity. On the other hand, the large accumulation of phy-
tanic acid, which exceeded that of pristanic acid under
these experimental conditions, pointed to a partial block
also at an early step of phytanic acid breakdown. Because
expression of phytanoyl-CoA hydroxylase was not down-
regulated in Scp2(−/−) mice (Fig. 6A), we hypothesized
that SCP2 could function as an auxiliary factor in phy-
tanic acid oxidation (i.e., by acting as a peroxisomal bind-
Figure 2. Peroxisomal proliferation and induction of b-oxida-
tion in Scp2(−/−) mice. (A) Diaminobenzidine staining of liver
sections. The bar indicates scale (bottom); the selected images
are representative for five animals of each strain. (B) Enzyme
activities (units/gram of wet weight) of catalase, mitochondrial
butyryl-CoA dehydrogenase (but-CoADH), ACO, and 3-ke-
tooctanoyl-CoA thiolase/(SCPx-thiol.) are shown. The activity
of the SCPx thiolase was determined after immunoprecipitation
with an antibody directed against the amino-terminal 383
amino acids of the protein. The columns represent ratios be-
tween Scp2(−/−) samples and controls ±S.D.; (***) paired t-test;
(P) < 0.005.
Figure 3. Altered gene expression in Scp2(−/−) mice. Northern
blots of liver RNA were hybridized with probes derived from
PEPCK, ACO, L-FABP, CYP7a, CYP27a, pTHIOL, and
mTHIOL. As a control for identical sample loading, Northern
blots were reprobed with a rat GADPH cDNA probe. The se-
lected images are representative for at least five animals of each
strain. The relative signal intensities were evaluated by laser
densitometry and are given in the text.
Table 2. Phytanic and pristanic acid in sera from Scp2 (+/+),
Scp 2 (+/−), and Scp2 (−/−) mice
Diet Scp2(+/+) Scp2(+/−) Scp2(−/−)
Phytanic
acid chow 1.4 ± 0.4 4.8 ± 2.6* 16 ± 3*
high fat 16 ± 6 33 ± 6* 152 ± 11*
5 mg/gram
phytol 129 ± 26 313 ± 44* 1163 ± 367*
Pristanic
acid chow < 0.5 < 0.5 < 0.5
high fat < 0.5 < 0.5 < 0.5
5 mg/gram
phytol 15 ± 8 17 ± 6 47 ± 26
Results are expressed in µmoles/liters as mean ±S.D. (n ù 5); (*)
paired t-test, P < 0.05. (< 0.5 µmole/liter) Not detectable. Quan-
titation and identification was performed by gas chromatogra-
phy of the carboxy-methylated derivatives by comparison with
appropriate standards. Details regarding the various diets are
described in Materials and Methods.
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ing protein or substrate carrier). To evaluate this possi-
bility, we determined binding affinities of phytanic acid,
pristanic acid, phytanoyl-CoA, pristanoyl-CoA, and cho-
lesterol of recombinant rat SCP2. We used a fluorescence
resonance energy transfer (FRET) competition assay. In
this assay, competitive inhibition of the binding of py-
renyl-dodecanoic acid to recombinant SCP2 by the non-
labeled substrates was monitored using FRET between
the single tryptophan residue of SCP2 (donor) and the
pyrene acceptor of the labeled fatty acid. The results
showed that the recombinant SCP2 protein had a high
affinity for phytanoyl-CoA binding (Kd, 250 nM), whereas
the affinities for binding of pristanoyl-CoA, pristanic
acid, and phytanic acid were considerably lower (Fig. 6B).
In addition, we found that the affinity of the interaction
between phytanoyl-CoA and SCP2 was severalfold
higher than that of cholesterol (which led to the tradi-
tional name sterol carrier protein) (Fig. 6B).
Diets containing up to 2.5 mg/gram of phytol were
tolerated rather well in Scp2(−/−) mice. Although body
weights declined slowly by up to 25% within 6 weeks,
we noticed no signs of toxicity. Apart from their skinny
appearance, Scp2(−/−) mice looked healthy, they re-
mained active, had no signs of neurological abnormali-
ties, and dietary intake was high until the end of the
experiment at 6 weeks. Mobilization of body mass was
maximal within the first few days and occurred in the
absence of significant differences in food intake (Fig. 7A).
In parallel, Scp2(−/−) mice developed more pronounced
hypolipidemia than controls (Fig. 7B). Higher phytol en-
richment of the diet (5 mg/gram) led to much more se-
vere abnormalities. Already beginning with the first day,
(−/−) mice lost body weight extensively, which declined
rapidly until they reached close to 60% of their starting
weights at the end of the second week (Fig. 7A), when we
noticed an unhealthy appearance, inactivity, reduced
muscle tone, ataxia, and peripheral neuropathy (uncoor-
dinated movements, unsteady gait, and trembling). Al-
ready after 1 week, Scp2(−/−) mice showed pronounced
decreases of lipid and glucose levels in serum and almost
complete absence of fat tissue (Fig. 7C). The values ob-
tained in serum for GPT, GOT, and alkaline phosphatase
were severalfold elevated and liver histology indicated
pronounced liver disease. All Scp2(−/−) mice died in the
third week, presumably because the extensive neurologi-
cal disturbances progressively disabled their food intake.
In contrast, controls tolerated both diets well until the
end of the experiment (6 weeks). When 5 mg/gram of
phytol were added to the diet, we observed only a mod-
erate decrease in body weight (−15%), mild hypolipid-
emia, and hypoglycemia, and moderately elevated serum
GPT levels without morphological signs of liver disease
or reduced food intake. In contrast, supplementation of
the diet with >50 mg of phytol per gram of food led to a
similar range of abnormalities and premature death in
controls, as could be observed with 5 mg/gram in the
transgenic strain (data not shown).
Discussion
In the present study, we used gene targeting to investi-
gate the function of Scp2 in mice. We were interested in
this approach because there is no human inherited dis-
ease known that results from Scp2 mutations and the
great manifold of in vitro studies, which were performed
during the past two decades, have not led to a convincing
functional conclusion. Because the defective allele con-
tained only one correctly targeted neo gene and the re-
combinant genetic abnormality based on a specific mo-
lecular mechanism, associated with exon 14 skipping
and thus abnormal splicing of Scp2 transcripts, it is
highly unlikely that the abnormalities are attributable to
a linked or incidental genetic defect rather than to the
Scp2 gene disruption itself. Moreover, also heterozygous
mice had elevated phytanic acid concentrations, indicat-
ing that this intermediate quantitative phenotype de-
pended on the gene dosage. Although the gene disruption
did not completely eliminate synthesis of Scp2 tran-
scripts, the abnormal RNAs were barely detectable and
encode truncated SCP2 and SCPx peptides that should be
functionally inactive and were not detected in Scp2(−/−)
mice. We conclude that the targeted allele is associated
with complete SCP2 and SCPx deficiency and thus, be-
haves like a null allele.
We believe our data demonstrate convincingly that ab-
normal phytol catabolism is a primary effect of the gene
disruption. Phytol is a natural tetramethyl-branched acyl
Figure 4. Phytanic acid levels and liver catalase activities in
Scp2(−/−) mice (j) and controls (d). Six- to 8-week-old male
mice were fed a standard chow diet supplemented with 2.5 mg/
gram of phytol for 4 days, followed by the standard diet without
phytol supplementation. Phytanic acid concentrations in serum
(n = 3) are given in µmoles/liter (top); catalase activities were
determined in liver and are expressed as arbitrary units/gram
wet weight (bottom).
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alcohol, originating from the isoprenoic side chain es-
terified to ring IV of chlorophyll. In humans, the daily
dietary intake of phytol and its product phytanic acid is
in the order of 100 mg/day, but intake varies greatly
depending on dietary habits (Steinberg 1995). As illus-
trated in Figure 8, normal catabolism starts with the con-
version of phytol to phytanic acid, followed by activation
to phytanoyl-CoA in the cytoplasm. Phytanoyl-CoA is
then imported into peroxisomes followed by a-oxida-
tion, which involves hydroxylation at the a-carbon po-
sition by phytanoyl-CoA hydroxylase (PHYH). Subse-
quently, 2-OH-phytanoyl-CoA is converted to pristanic
acid and formyl-CoA (Wanders et al. 1994; Croes et al.
1997). Whereas formyl-CoA is further catabolized in
mitochondria, pristanic acid is activated to pristanoyl-
CoA, which is then subject to six cycles of peroxisomal
b-oxidation. The intermediates of the first cycle are
D2,3-pristenoyl-CoA (produced by pristanoyl-CoA oxi-
dase), 3-OH-pristanoyl-CoA, and 3-ketopristanoyl-CoA
(produced by a peroxisomal bifunctional enzyme). Finally,
3-ketopristanoyl-CoA is substrate for thiolytic cleavage,
catalyzed by a 3-ketopristanoyl-CoA thiolase, which yields
the (n-3) lower homolog of pristanoyl-CoA (4,8,12-trimeth-
yltridecanoyl-CoA) and propionyl-CoA (for review, see
Steinberg 1995). Although studies on mice are not avail-
able, it now appears that this pathway operates in a similar
way in rats and humans (Watkins et al. 1994; Singh and
Poulos 1995).
We detected pronounced accumulation of phytanic
acid in Scp2(−/−) mice, which exceeded that of pristanic
acid and the downstream catabolic intermediates by sev-
eralfold. This may be explained by inhibition of initial
phytanic acid activation, phytanoyl-CoA import into
peroxisomes, or phytanoyl-CoA a-hydroxylation. Abnor-
mal activation was unlikely because recent studies dem-
onstrated convincingly that phytanoyl-CoA ligation is
mediated by a common long chain fatty acyl-CoA ligase
(Watkins et al. 1996), whereas metabolism of long
straight chain fatty acids was apparently not affected by
the gene disruption. Because PHYH was expressed nor-
Figure 5. Defective phytol catabolism in Scp2(−/−) mice. (A) Detection of phytanic acid and its catabolic metabolites in the liver by
TOF-SIMS analysis. (Top) Mass spectrum of the phytanic acid standard (1 pg). The compound was detected as a negative ion at 311.5
mu, representing the [M-H+]− ion. (Middle) Lipid extracts were prepared from liver of Scp2(−/−) mice and subjected to TOF-SIMS
analysis using identical conditions as for the standard. Arrows point to phytanic acid (311.5 mu), and the expected signals for
D2,3-pristenic acid (295.5 mu), pristanic acid (297.5 mu), and 3-OH-pristanic acid (313.5 mu). The signals obtained for the 18 carbon
atoms straight chain fatty acids C18:0, C18:1, and C18:2 are also marked. (Bottom) The same analysis with a liver sample from an
Scp2(+/+) mouse. The images are representative for five mice of each genotype and both sexes. (B) Monitoring of ions corresponding
to the predicted products of thiolase-mediated 3-ketopristanoyl-CoA cleavage (at 255.5 mu, TMTDA; at 253.5 mu, D2,3-TMTDA). (C)
Quantitative evaluation of the signal intensities based on five mice of each strain and sex. The columns indicate mean values of fold
difference between either (−/−) mice or controls; ±S.E.M.. Black bars (−/−); hatched bars (+/+).
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mally in Scp2(−/−) mice, we also excluded secondary
down-regulation of PHYH expression. On the basis of
these considerations, we hypothesized that the lipid car-
rier function of SCP2 may be involved in peroxisomal
phytanoyl-CoA uptake (i.e., by acting as phytanoyl-CoA
binding protein). The analysis, which was performed
with a very specific FRET competition assay on the pu-
rified recombinant rat protein, revealed a much higher
affinity for binding of phytanoyl-CoA than of pristanoyl-
CoA, phytanic acid, pristanic acid, or cholesterol. In ad-
dition, the Kd value was within a physiologically mean-
ingful range (250 nM), thus supporting the postulated in-
direct role of SCP2 in peroxisomal phytanoyl-CoA
uptake.
Impaired phytanoyl-CoA import into peroxisomes
would lead to the expectation that the production of
downstream intermediates, which are generated in per-
oxisomes from phytanoyl-CoA, should be repressed in
Scp2(−/−) mice. In contrast, evaluation of TOF-SIMS sig-
nals, which corresponded to these intermediates, indi-
cated even higher concentrations than in controls after
challenging mice with high dosages of dietary phytol.
Although the twofold increase in pristanic acid did not
reach statistical significance, accumulation of D2,3-pris-
tenic acid (four- to fivefold) and 3-OH-pristanic acid
(three- to fourfold) was highly significant. In contrast,
3-ketopristanic acid was not stable enough to withstand
alkaline extraction and subsequent TOF-SIMS or GC-MS
analyses. We could, however, detect a very significant
70% repression of the signals produced by the down-
stream products of the 3-ketopristanoyl-CoA thiolase re-
action in Scp2(−/−) mice (4,8,12-trimethyltridecanoic
acid and 4,8,12-trimethyl-D2,3-tridecenoic acid). To-
gether with enrichment of upstream intermediates in
pristanic acid b-oxidation, the latter result supported
very clearly inhibition at the level of 3-ketopristanoyl-
CoA cleavage. These in vivo data corresponded to recent
studies, which demonstrated high specific activity of re-
combinant rat SCPx to catalyze the thiolytic cleavage of
3-ketopristanoyl-CoA in vitro (Wanders et al. 1997).
Thus, our data appear to indicate a dual effect of the gene
disruption, consisting of reduced peroxisomal phytanoyl-
CoA import combined with defective thiolytic cleavage
of 3-ketopristanoyl-CoA. Whereas the first effect seems
to relate to the phytanoyl-CoA carrier function of SCP2,
the second may reflect the enzymatic activity associated
with SCPx. This hypothesis appears very compelling, be-
cause it may clarify why evolution has established a mo-
lecular basis for coexpression of the two Scp2-encoded
functions by fusing two originally separated SCP2 and
thiolase genes into one common transcriptional unit.
The fused gene is present in all vertebrates and could be
traced back to Drosophila melanogaster (GenBank ac-
cession no. X97685). In contrast, two separated genes
were identified in Caenorhabditis elegans and several
yeast species (Pfeifer et al. 1993b; Bunya et al. 1997).
Interestingly, an ancient precursor of SCP2 could be
identified even in the primitive methanogenic archaeon
Methanococcus jannaschii (Bult et al. 1996), in whom
methyl-branched fatty acids play a prominent role.
As expected, (−/−) mice revealed a higher increase of
phytanic acid concentrations than controls, when we
challenged the two strains of mice transiently with phy-
tol-enriched diets. However, after switching to the low
phytol diet, Scp2(−/−) mice eliminated phytanic acid
from the bloodstream at a surprisingly high initial rate,
followed by a much slower decline after 6 days. Because
it is known from studies on patients with Refsum dis-
ease that excess phytanic acid can be taken up by cells
and stored in triglycerides (Steinberg 1995), the high ini-
tial rate most likely reflected cellular uptake and storage
rather than high residual activity for phytanic acid
breakdown. On the basis of the slow rate of the late
decline, we calculated this activity to ∼10%. This was in
line with our other findings—10-fold higher steady-state
concentrations of phytanic acid and ∼10-fold increased
phytol toxicity. However, whether the residual activity
is attributable to compensatory up-regulation of peroxi-
somal straight chain b-oxidation, the presence in our
model of the SCP2-like activity associated with the 80-
kD precursor of 17b-hydroxysteroid dehydrogenase type
Figure 6. Expression of phytanoyl-CoA hydroxylase in Scp2(−/−)
mice. Northern blots of liver RNA were hybridized with a la-
beled PYHH cDNA probe (A). Specific phytanoyl-CoA-binding
activity of recombinant rat SCP2 (B). The columns represent
means of 1/Kd ± S.D. of five independent determinations.
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IV (Leenders et al. 1996), or an alternative pathway for
phytanic acid oxidation, cannot be decided from our
data.
Baum et al. (1997) reported that overexpression of
SCP2 in rat hepatoma cells inhibited cholesterol esteri-
fication and HDL secretion, whereas plasma membrane
cholesterol was significantly increased. In addition,
Puglielli et al. (1995) showed that treatment of human
skin fibroblasts with SCP2 anti-sense oligonucleotides
led to inhibition of cholesterol net transfer to the plasma
membrane. In view of these results, we found it surpris-
ing that Scp2(−/−) mice had significantly lower hepatic
cholesterol ester storage than controls. Because the gene
disruption also lowered free fatty acid and triglyceride
concentrations very effectively, our results seem to in-
dicate decreased availability of fatty acids for intracellu-
lar lipid esterification rather than a specific abnormality
in cytosolic free cholesterol trafficking. It appeared in-
teresting to us that hepatic hypolipidemia was associ-
ated with peroxisome proliferation and induction of per-
oxisomal and mitochondrial fatty acid b-oxidation in
Scp2(−/−) mice. As is known from treatment of rodents
with fibrates, induction of b-oxidation and peroxisome
proliferation can lead to fatty acid hypermetabolism and
hypolipidemia (for review, see Lemberger et al. 1996).
The signals mediating peroxisome proliferation and
modulation of gene expression in Scp2(−/−) mice are cur-
rently unknown. One possibility consists of a direct or
indirect effect of accumulating phytol metabolites on
nuclear signal transduction pathways (i.e., the peroxi-
some proliferator activated receptor PPARa being the
most likely candidate in this respect).
Earlier studies provided several lines of indirect evi-
dence that appear to support a role for SCP2 in adrenal
and ovarian steroidogenesis (Pfeifer et al. 1993a). SCP2 is
abundant in steroidogenic glands and trophic hormones
stimulate steroidogenesis along with SCP2 gene expres-
sion (Trzeciak et al. 1987; Rennert et al. 1991). In addi-
tion, SCP2 enhanced the movement of cholesterol be-
tween vesicles and isolated mitochondria in vitro, which
corresponded to increased pregnenolone synthesis in the
in vitro system (Chanderbhan et al. 1982; Xu et al. 1991).
Moreover, overexpression of SCP2 in COS cells engi-
neered to produce progestins increased steroid formation
(Yamamoto et al. 1991). On the other hand, no correla-
tion existed between SCP2 expression and side chain
cleavage activity in a variety of human tissue specimen
(Yanase et al. 1996) and, a priori, it is not very clear how
a peroxisomal protein would stimulate the net transfer
of free cholesterol to mitochondria directly. So far, the
phenotypic characterization of the Scp2(−/−) mouse has
not provided any convincing evidence for a role of SCP2
in steroidogenesis in vivo. The absence of developmental
abnormalities or salt wasting and the fact that (−/−) mice
had no abnormalities affecting fertility, seemed to ex-
clude an obligatory role of SCP2 in general steroidogen-
esis. This was in line with normal adrenal morphology
and normal plasma concentrations of testosterone, pro-
gesterone, and glucocorticoids. On the other hand, a
more subtle defect may be masked by compensatory
mechanisms or depend on appropriate stress conditions.
In summary, the current phenotypic characterization
of the Scp2(−/−) KO mouse model did not provide im-
mediate convincing evidence for an obligatory role of
Figure 7. Phenotypic abnormalities in
Scp2(−/−) mice after dietary phytol en-
richment. (A) Six- to 8-week-old male
mice (n = 5 in each group) were fed the
standard chow diet (control) or the same
diet supplemented with 2.5 or 5 mg/
gram of phytol for up to 6 weeks. Body
weights (top) and food intake (bottom,
given as grams of food consumed in the
4-day period) were monitored daily. Re-
sults were obtained for the first 4 days,
when decline of body weight was maxi-
mal. When Scp2(−/−) mice were fed the
diet containing 5 mg/gram of phytol,
they continued to mobilize body mass
until they reached close to 60% of their
starting weights. In the third week, they
developed neuropathy, reduced their
food intake, and died. (B) Serum triglyc-
eride concentrations in the six experi-
mental groups. The columns represent
means ± S.D.. (C) Abdominal tissues in
(+/+) (left) and (−/−) mice (right) after 10
days on the 5 mg/gram phytol diet. Note
the normal appearance of the kidneys
but hyperplastic and dark structures of
the adrenal glands. In addition, lack of virtually any fat tissue, which is prominent in the (+/+) mouse, is evident in the (−/−) mouse.
The abnormalities developed in the absence of significant reductions in food intake.
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this gene in intracellular cholesterol trafficking. Instead,
our data indicate that the two gene products SCP2 and
SCPx cooperate in peroxisomal oxidation of certain
naturally occurring tetramethyl-branched fatty acyl-
CoAs in mice. Thus, the Scp2 gene is somewhat remi-
niscent of a bacterial operon, in which distinct functions
that act in the same metabolic pathway are combined in
a common transcriptional unit. This role is consistent
with its genetic organization, the well-established per-
oxisomal localization of SCP2 and SCPx (Keller et al.
1989; Ossendorp and Wirtz 1993), the ability of SCP2 to
bind phytanoyl-CoA in vitro, high 3-ketopristanoyl-CoA
thiolase activity of the SCPx protein (Wanders et al.
1997), and the expression pattern that correlates with
lipid uptake of cells and thus phytanic acid exposition
(Ossendorp et al. 1991; Seedorf and Assmann 1991; Ya-
mamoto et al. 1991; Hirai et al. 1994; McLean et al.
1995).
Materials and methods
Construction of the targeting vector
Scp2 genomic sequences were isolated from a l-Fix mouse ge-
nomic library (provided by Stratagene, Heidelberg, Germany)
made of leukocyte DNA from mouse strain 129/SV. The basic
fragment of the targeting construct was a 7.7-kb genomic EcoRI
fragment containing exon 14 as the only Scp2 coding sequences.
Because exon 14 did not contain an appropriate restriction site,
a 1.8-kb HindIII–SpeI fragment including the exon and flanking
intron sequences was first subcloned in pBluescript SK− and a
SalI site was introduced into exon 14 by PCR-mediated site-
directed mutagenesis (wild-type sequence, 58-GTGAAG; mu-
tated sequence, 58-GTCGACG). The mutated fragment was re-
introduced into the original 7.7-kb EcoRI fragment and this frag-
ment was then cloned in the EcoRI site of a modified
pBluescript vector (lacking the restriction sites HindII, HindIII,
SalI, EcoRV, and SpeI from its multicloning site). Double diges-
tion of this vector with SalI and SpeI released a 250-bp DNA
fragment containing 110 bp of the exon 14 38-part and 140 bp of
flanking intron 14 sequences. After treatment with Klenow en-
zyme, the 1.2-kb XhoI–HindII fragment containing the neo gene
cassette from the vector pMC1neoPoly(A) was blunt-end cloned
into the double digested vector, thereby replacing the exon 14–
intron 14 region of the Scp2 gene by the neo gene cassette. The
8.7-kb NotI–KpnI fragment from the resulting vector was cloned
into the vector pPNT that was linearized by NotI digestion and
used for transfection of ES cells.
Culturing and electroporation of ES cells
Experiments were carried out with the strain 129/Ola-derived
ES cell line E14 (Hooper et al. 1987) provided by N. Maeda
Figure 8. Schematic representation of mammalian phytol metabolism. Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) re-
sults either directly from the diet or from oxidation of dietary phytol. Note that phytanic acid must be decarboxylated to pristanic acid
before entering peroxisomal b-oxidation, because the b-carbon atom is blocked by the 3-methyl group. Presumed intermediates of
a-oxidation are 2-OH-phytanoyl-CoA and pristanal, but the precise cofactor requirements are currently unknown. Enoyl-CoA hydra-
tase/3-OH-acyl-CoA dehydrogenase: peroxisomal bifunctional enzyme (PBE).
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(University of North Carolina). The cells were cultured on
G418-resistant mouse embryonic fibroblast feeder layers as de-
scribed earlier (Zhang et al. 1992). ES cells (3 × 107 cells) were
resuspended in 0.5 ml of PBS containing 25 µg of linearized
targeting vector and electroporated for 1 sec with a Bio-Rad
GenePulser at 200 µF and 300 V per 0.4 cm. Cells were then
seeded on eight Petri dishes (diameter, 10 cm) coated with fi-
broblast feeder layers. Selection with G418 (200 µg/ml, GIBCO)
was started after 1 day and selection with gancyclovir (2 µM)
after 2 days. After 12 days of growth, individual colonies were
picked. Each colony was scraped from the plate with a sterile
glass capillary and transferred to a 24-multiwell plate coated
with fibroblast feeder layers and containing 1 ml of growth me-
dium supplemented with 200 µg/ml G418, 2 µM Gancyclovir,
and 100 U/ml of penicillin and streptomycin. After 2 days, each
colony was disrupted with trypsin [0.025% wt/vol]. Four to 8
days later, the cells were trypsinized again and ∼90 % of the
cells were removed for DNA isolation. The remaining cells
were transferred into new coated multiwell plates and after the
cells were grown to a final density of 1.5 × 106 to 2.5 × 106 cells
per well, they were frozen in growth medium containing 10%
dimethylsulfoxide.
DNA analysis of ES cells and mice
Cells were lysed in 200 µl of 1% SDS, 25 µg of proteinase K per
milliliter for 12–16 hr at 55°C. Thereafter, 100 µl of saturated
NaCl was added, mixed, and centrifuged in an Eppendorf bench-
top centrifuge at maximal speed for 15 min. The DNA was
ethanol precipitated from the supernatant and dissolved in 25 µl
of Tris-EDTA buffer (TE). Eight microliters of this solution was
digested with the appropriate restriction enzyme, fractionated
in 0.8% agarose gels and transferred to nitrocellulose (0.1-µm
pore size; Schleicher & Schuell). Hybridization was performed
as described (Raabe et al. 1996) with final washes in 0.1× SSC,
0.1% (wt/vol) SDS at 65°C for 30 min. DNA for genotype analy-
sis was isolated from mouse tail tips as described by Laird et al.
(1991).
RNA and Western blot analyses, PCR, and DNA sequencing
Total RNA was isolated from mouse tissues with the guandini-
um–thiocyanate–phenol–chloroform extraction procedure (Chom-
czynski and Sacchi 1987) followed by selection of poly(A) RNA
on oligo(dT) cellulose. Northern blots were hybridized with di-
goxigenin-labeled probes prepared by random priming using a
commercially available kit (Boehringer, Mannheim, Germany).
All probes were obtained from a mouse liver cDNA library by
PCR amplification with appropriate primers. Quantification
was carried out relative to expression of GAPDH, detected with
a probe derived from a 1.3-kb PstI fragment from pGAPDH (Fort
et al. 1985) containing rat glyceraldehyde-3-phosphate dehydro-
genase cDNA, the probe for detection of Scp2 expression was a
0.45-kb PstI fragment from pBS-mSCPx containing mouse sterol
carrier protein X cDNA (Seedorf et al. 1993). The membranes
were rinsed twice in 0.1% SDS, 2× SSC at room temperature and
then twice in 1% SDS, 0.5× SSC at 68°C for 15 min. Bands were
visualized using the chemiluminescence substrate CDP-Star
(Tropix-Serva, Heidelberg, Germany). DNA sequencing was per-
formed on an automated laser fluorescence DNA sequencer
(Pharmacia, Upsala, Sweden) according to the instruction
manual of the supplier. Detection of SCP2-related peptides by
Western blot analysis was described earlier (Seedorf et al.
1994a).
Dietary intervention studies, and histological and
anatomical analyses
In most experiments, 6- to 24-week-old male mice were used.
However, the defect in phytol catabolism was confirmed to be
present also in a group of 25 female mice. Mice were fed a
standard chow diet [(Altrumin, Hanover, Germany) containing
0.8 mg/gram (wt/wt) of various sterols, mainly cholesterol and
b-sitosterol, 0.075 mg/gram (wt/wt) of nonesterified phytol and
0.2 mg/gram (wt/wt) of phytanic acid] and water of pH 3.4–3.6
ad libitum. The high fat diet consisted of standard chow supple-
mented with 1% cholesterol, 15% coconut butter, and 0.5%
cholate. Phytol-enriched diets were prepared from these diets by
adding 1–50 mg/gram (wt/wt) of phytol (Aldrich, St. Louis,
MO). Animals were kept individually, and food intake and body
weights were monitored daily. Tissues were dissected routinely
between 9 and 10 a.m. (to exclude variations that might be
attributable to circadian regulation) after lethal anesthesia with
avertin (Sigma). Tissues were fixed in phosphate-buffered form-
aldehyde (pH 7.2) embedded in paraffin, sectioned at 5 µm, and
stained with appropriate stains.
Binding of fatty acids to SCP2
Binding constants for the interaction between recombinant rat
SCP2 and phytanic acid, phytanoyl-CoA, pristanic acid, or pris-
tanoyl-CoA were determined by competing bound pyrene-la-
beled dodecanoic acid with the nonlabeled substrates. Binding
of pyrenyl-dodecanoic acid was monitored using FRET between
the single tryptophan residue of SCP2 (donor) and the pyrene
acceptor of the labeled fatty acid. The signals were corrected for
direct excitation of pyrene at 280 nm. The competitor-induced
decrease in sensitized emission was fitted to a binding equation
derived from the rate equations of the relevant bimolar binding
reactions.
Analytical techniques, serum chemistry, and statistical
analyses
Serum samples were taken by orbital bleeding or heart punc-
ture. Serum chemistry was performed by routine clinical tests
on a Hitachi 747 analyzer with sample volumes of 0.15 ml.
Hormones were measured using commercially available radio-
immunoassay kits (Diagnostic Products Corp., Los Angeles,
CA). Fatty acids and phytanic and pristanic acid in serum were
measured by gas chromatography. Identification was achieved
with appropriate standards and verified by mass spectrometry as
described earlier. Analyses in the liver of phytol metabolites
were performed by TOF-SIMS as described earlier (Seedorf et al.
1995). All measurements were performed at least in triplicates.
Statistical analyses were performed with the paired t-test. Val-
ues of P ø 0.05 were considered statistically significant.
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